New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
06:16 EDTSNTASynta Pharmaceuticals announces positive interim results from ganetespib trial
Synta Pharmaceuticals announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The ENCHANT-1 trial was designed to evaluate ganetespib single agent activity in metastatic breast cancer and identify potential predictive biomarkers. Target enrollment is 35 patients in three cohorts, which include HER2+ breast cancer, triple-negative breast cancer, and, recently added and now recruiting, ER/PR-positive patients previously untreated for locally advanced or metastatic disease. The goal of the trial design is to obtain initial evidence of a clinical activity signal with single-agent ganetespib administered for up to 12 weeks. Professor David Cameron, Professor of Oncology and Director of Cancer Services, NHS Lothian stated, “Ganetespib appears to not only overcome the challenges of earlier-generation Hsp90 inhibitors, with a good tolerability profile, but demonstrates highly encouraging single-agent activity in both HER2+ and triple-negative disease. These results warrant expanded study of ganetespib in this metastatic disease setting.”
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNTA

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use